Current and future strategies for the treatment of chronic hepatitis C
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Chronic hepatitis C infection is a major cause of liver disease and hepatocellular carcinoma worldwide. While hepatitis C has been treated for decades with some success, the introduction of direct acting antiviral agents has revolutionized the treatment of hepatitis C with finite, highly effective, well-tolerated therapy and there are few populations that cannot be successfully treated now or are complicated to manage. The World Health Organization has released elimination targets in an effort to eliminate viral hepatitis and reduce dramatically the morbidity and mortality caused by both viral hepatitis. While hepatitis C is straightforward to treat, it remains problematic to eliminate on a global scale. Diagnosis of hepatitis C remains the major gap in the cascade of care and numerous screening strategies will be required to reduce this gap. While historically, treatment of hepatitis C has been centralized, decentralized approaches will be required to diagnose, evaluate, and link to care the large population of individuals worldwide with hepatitis C across low-, middle-, and high-income countries. With the introduction of multiple pangenotypic treatment options and reduced cost for these therapies, assessment and treatment for those with hepatitis C has been simplified and made more accessible worldwide. There are multiple populations for whom care models are being developed and refined, including those when inject drugs, those who are incarcerated, those who present with sexually transmitted disease including the men who have sex with men population, amongst many others. While a vaccine for hepatitis C remains elusive these efforts continue. Multiple successful elimination efforts have been reported.
Abstract
Chronic hepatitis C infection is a major cause of liver disease and hepatocellular carcinoma worldwide. While hepatitis C has been treated for decades with some success, the introduction of direct acting antiviral agents has revolutionized the treatment of hepatitis C with finite, highly effective, well-tolerated therapy and there are few populations that cannot be successfully treated now or are complicated to manage. The World Health Organization has released elimination targets in an effort to eliminate viral hepatitis and reduce dramatically the morbidity and mortality caused by both viral hepatitis. While hepatitis C is straightforward to treat, it remains problematic to eliminate on a global scale. Diagnosis of hepatitis C remains the major gap in the cascade of care and numerous screening strategies will be required to reduce this gap. While historically, treatment of hepatitis C has been centralized, decentralized approaches will be required to diagnose, evaluate, and link to care the large population of individuals worldwide with hepatitis C across low-, middle-, and high-income countries. With the introduction of multiple pangenotypic treatment options and reduced cost for these therapies, assessment and treatment for those with hepatitis C has been simplified and made more accessible worldwide. There are multiple populations for whom care models are being developed and refined, including those when inject drugs, those who are incarcerated, those who present with sexually transmitted disease including the men who have sex with men population, amongst many others. While a vaccine for hepatitis C remains elusive these efforts continue. Multiple successful elimination efforts have been reported.
참고문헌 (48)
- Kuo G, "An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis", Science, 244, pp.362~364 (1989)
- Choo QL, "Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome", Science, 244, pp.359~362 (1989)
- Appelbaum E, "Artificial transmission of viral hepatitis among intravenous diacetylmorphine addicts", J Am Med Assoc, 147, pp.222~224 (1951)
- Davis GL, "Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial", N Engl J Med, 321, pp.1501~1506 (1989)
- Hoofnagle JH, "Peginterferon and ribavirin for chronic hepatitis C", N Engl J Med, 355, pp.2444~2451 (2006)
- Falade-Nwulia O, "Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review", Ann Intern Med, 166, pp.637~648 (2017)
- Polaris Observatory HCV Collaborators, "Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study", Lancet Gastroenterol Hepatol, 2, pp.161~176 (2017)
- World Health Organization (WHO), "Towards ending viral hepatitis" (2016), WHO
- Lazarus JV, "Hepatitis C virus epidemiology and the impact of interferon-free hepatitis C virus therapy", Cold Spring Harb Perspect Med, 10, pp.a036913~ (2020)
- Dillon JF, "Urgent action to fight hepatitis C in people who inject drugs in Europe", Hepatol Med Policy, 1, pp.2~ (2016)
- Zhang AY, "The changing epidemiology of candidemia in the United States:injection drug use as an increasingly common risk factor-active surveillance in selected sites, United States, 2014-2017", Clin Infect Dis, 71, pp.1732~1737 (2020)
- Grebely J, "Can hepatitis C virus infection be eradicated in people who inject drugs?", Antiviral Res, 104, pp.62~72 (2014)
- Ryerson AB, "Vital signs:newly reported acute and chronic hepatitis C cases - United States, 2009-2018", MMWR Morb Mortal Wkly Rep, 69, pp.399~404 (2020)
- Dolan K, "Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees", Lancet, 388, pp.1089~1102 (2016)
- Kinner SA, "Agespecific global prevalence of hepatitis B, hepatitis C, HIV, and tuberculosis among incarcerated people: a systematic review", J Adolesc Health, 62, pp.S18~S26 (2018)
- Flemming JA, "Reduction in liver transplant wait‐listing in the era of direct‐acting antiviral therapy", Hepatology, 65, pp.804~812 (2017)
- Dore GJ, "Universal screening for hepatitis C virus infection should be linked to universal treatment access", Nat Rev Gastroenterol Hepatol, 17, pp.321~322 (2020)
- Graham CS, "Universal screening for hepatitis C virus infection: a step toward elimination", JAMA, 323, pp.936~937 (2020)
- US Preventive Services Task Force; Owens DK, "Screening for hepatitis C virus infection in adolescents and adults: US preventive services task force recommendation statement", JAMA, 323, pp.970~975 (2020)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2018", J Hepatol, 69, pp.461~511 (2018)
- Omata M, "APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing", Hepatol Int, 10, pp.681~701 (2016)
- World Health Organization (WHO), "WHO guidelines on hepatitis B and C testing" (2017), WHO
- Mathur P, "Hepatitis C core antigen testing: still an effective diagnostic method for global elimination of hepatitis C", Clin Infect Dis, 70, pp.674~675 (2020)
- Bethea ED, "Should we treat acute hepatitis C? A decision and cost-effectiveness analysis", Hepatology, 67, pp.837~846 (2018)
- Ghany MG, "Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection", Hepatology, 71, pp.686~721 (2020)
- Dieterich DT, "A simplified algorithm for the management of hepatitis C infection", Gastroenterol Hepatol, 15(5 Suppl 3), pp.1~12 (2019)
- Dore GJ, "Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial", Ann Intern Med, 165, pp.625~634 (2016)
- Graf C, "Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis", Clin Infect Dis, 70, pp.2355~2365 (2020)
- Jin F, "Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review", Sex Health, 14, pp.28~41 (2017)
- Pufall EL, "Sexualized drug use (‘chemsex’) and high‐risk sexual behaviours in HIV‐positive men who have sex with men", HIV Med, 19, pp.261~270 (2018)
- Hoornenborg E, "MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection", AIDS, 31, pp.1603~1610 (2017)
- Boerekamps A, "Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy", Clin Infect Dis, 66, pp.1360~1365 (2018)
- Rosenthal ES, "Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs", Clin Infect Dis, 71, pp.1715~1722 (2020)
- Scott N, "Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020", J Hepatol, 68, pp.932~939 (2018)
- Arora S, "Project ECHO: democratising knowledge for the elimination of viral hepatitis", Lancet Gastroenterol Hepatol, 4, pp.91~93 (2019)
- Dhiman RK, "Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting", J Hepatol, 71, pp.1076~1085 (2019)
- Waked I, "Screening and treatment program to eliminate hepatitis C in Egypt", N Engl J Med, 382, pp.1166~1174 (2020)
- Chen DS, "Taiwan commits to eliminating hepatitis C in 2025", Lancet Infect Dis, 19, pp.466~467 (2019)
- Wu GH, "Taiwan is on track of accelerating hepatitis C elimination by 2025", Liver Int, 40, pp.1506~1507 (2020)
- Sinn DH, "Current status and strategies for viral hepatitis control in Korea", Clin Mol Hepatol, 23, pp.189~195 (2017)
- Hagan LM, "Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination", BMC Public Health, 19(Suppl 3), pp.480~ (2019)
- Tsertsvadze T, "Three years of progress toward achieving hepatitis C elimination in the country of Georgia, April 2015-March 2018", Clin Infect Dis, 71, pp.1263~1268 (2020)
- Umutesi G, "Rwanda launches a 5-year national hepatitis C elimination plan: a landmark in sub-Saharan Africa", J Hepatol, 70, pp.1043~1045 (2019)
- Connoley D, "Detection, stratification and treatment of hepatitis C-positive prisoners in the United Kingdom prison estate: development of a pathway of care to facilitate the elimination of hepatitis C in a London prison", J Viral Hepat, 27, pp.987~995 (2020)
- Smith DB, "Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource", Hepatology, 59, pp.318~327 (2014)
- Bailey JR, "Approaches, progress, and challenges to hepatitis C vaccine development", Gastroenterology, 156, pp.418~430 (2019)
- "Progress report on access to hepatitis c treatment: focus on overcoming barriers in low- and middle-income countries" (2018)[URL]
- "In vitro diagnostics and laboratory technology"[URL]